Magnetic brain stimulation to study involuntary movements in Parkinson's disease
Tests magnetic brain stimulation against sham in people with Parkinson's and levodopa-induced dyskinesia.
Plain-language title generated from the registry record
Registry title: rTMS as an Intervention for Levodopa-induced Dyskinesia
Key facts
- Where
- Hvidovre, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06570824, who can take part
Where in Denmark
- DRCMRHvidovre, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Danish Research Centre for Magnetic Resonance
- Trial code
- NCT06570824
- Record updated
- 27 August 2026
- Original description
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.Read full original descriptionShow less
Network Based Repetitive Transcranial Magnetic Stimulation (rTMS) as an Intervention for Levodopa-induced Dyskinesia (LID) in Parkinson's Disease (PD)
The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.
Inclusion: Clinically established or probable PD; Clinical Diagnostic Criteria for Parkinson's Disease; Peak-of-dose levodopa-induced dyskinesia; Stable antiparkinsonian medicine for at least four weeks; Signed informed consent.
Exclusion: Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin); Psychiatric disorders; History of neurological disease other than Parkinson's disease; History of epilepsy/conditions associated with increased risk to seizure-induction through TMS; Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS; Female participants of childbearing age must not be pregnant and that they must use contraception during the trial; Regular usage of benzodiazepines and opioids (more than once per week); Contraindications for MRI scan; Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.